What is the mechanism of action (MOA) of dirlotapide (Solentrol)?

Dirlotapide, marketed as Solentrol, primarily functions as a selective microsomal triglyceride transfer protein inhibitor. This mechanism of action is significant in the context of its use for weight management in dogs. By inhibiting the microsomal triglyceride transfer protein (MTP), dirlotapide disrupts the normal packaging and transport of triglycerides and very low-density lipoproteins (VLDL) within the liver. This leads to a decrease in the absorption of dietary fats and the synthesis of triglycerides, ultimately resulting in a reduction of overall body weight and fat stores in the treated animals.

The effectiveness of this mechanism is particularly evident in animal models where it has shown to enable weight loss while also having minimal adverse effects compared to other anti-obesity medications. This highlights dirlotapide's role in managing obesity through a targeted approach to lipid metabolism.